XBI SPDR S&P Biotech ETF
Neutral Confidence 0.04 Regime Mid-vol
Maintain neutral stance. The leading arc 63 (hantavirus_outbreak) is outdated and lacks relevant non-price catalysts: days_since_event≈48.6, strengthen_streak=0, weaken_streak=19; the forecasted probability of market outbreak remains at ~0.01–0.02. Option IV data is sparse with no confirmed cases or regulatory support evidence. The arc also clearly indicates that prices are over-anticipated (price_in_excess=+11.96%, flagged=True), and borrow fees/availability do not point to significant short squeeze. CMS/Medicare documents have a moderately negative bias for the sector. Given the mixed cross-asset environment (VIX term ratio≈0.987, slight increase in Fed net liquidity), no new non-price evidence drives directional change; thus, continue to maintain neutral stance with low confidence.
30-day verdict history
| Date | Direction | Confidence | Thesis |
|---|---|---|---|
| 2026-07-17 | Neutral | 0.04 | Maintain neutral stance. The leading arc 63 (hantavirus_outbreak) is outdated and lacks relevant non-price catalysts: days_since_event≈48.6, strengthen_streak=0, weaken_streak=19; the forecasted probability of market outbreak remains at ~0.01–0.02. Option IV data is sparse with no confirmed cases or regulatory support evidence. The arc also clearly indicates that prices are over-anticipated (price_in_excess=+11.96%, flagged=True), and borrow fees/availability do not point to significant short squeeze. CMS/Medicare documents have a moderately negative bias for the sector. Given the mixed cross-asset environment (VIX term ratio≈0.987, slight increase in Fed net liquidity), no new non-price evidence drives directional change; thus, continue to maintain neutral stance with low confidence. |
| 2026-07-16 | Neutral | 0.03 | Maintain neutral. The dominant arc 63 (hantavirus_outbreak) is outdated (days_since_event≈48, strengthen_streak=0, weaken_streak=19), and heavily priced in (+14.51%, flagged=True), thus no new non-price evidence supports a position; independent non-price signals also do not support it (predicted market disease probability ≈0.02, no new confirmed cases or policy catalysts, and net outflows in the near term). In a calm contango environment, with no verifiable macro/fundamental drivers, and given that |
| 2026-07-15 | Neutral | 0.05 | Maintain neutral stance. The primary driver arc 63 (hantavirus_outbreak) remains outdated and heavily priced in (price_in_excess=+14.34%, flagged=True), with non-price evidence not supporting additional bullishness: Polymarket outbreak probability is very low, near-month net outflows and rising borrow fees indicate a bias towards liquidity withdrawal, and strengthen_streak=0/weaken_streak=18, days_since_event=46.7 suggest information decay. A calm contango macro/risk environment does not provide new directional reasons, thus maintaining neutral stance with low confidence and waiting for new empirical catalysts or substantial changes in the market/liquidity. |
| 2026-07-14 | Neutral | 0.04 | Maintain neutral stance. The primary driver arc 63 (hantavirus_outbreak) is outdated: days_since_event ≈45.6 and strengthen_streak=0/weaken_streak=17, with the arc marked as price_in_excess (+14.61%, flag=True), indicating that the market has already factored in significant premium; non-price evidence (Polymarket outbreak probability ≈0.01, recent net outflow of AUM -0.76% and slight rise in borrow fees) does not support a new directional bet. Current macro/risk appetite (VIX term ratio 0.935, HY OAS 2.69%) is stable/favorable for risk assets, but this is non-directional background and does not constitute a positive catalyst for XBI positioning; therefore, maintain neutral stance and remain cautious about the existing price premium (priced-in). |
| 2026-07-13 | Neutral | 0.03 | Maintain neutral stance. The primary driver arc 63 (hantavirus_outbreak) is a stale signal: days_since_event ≈44.9 and strengthen_streak=0, with the yes_prob of large-scale spread predicted at only around 0.06. Option chain liquidity is sparse, providing insufficient non-price evidence for directional judgment. This arc is also marked as price_in_excess (+16.55% and flag=True), indicating that the related premium has already been factored into the market; despite the overall friendly macro/liquidity environment for risk assets, this constitutes only indirect support and does not serve as a non-price basis for establishing long or short positions. |
| 2026-07-12 | Neutral | 0.02 | Maintain neutral. The primary driver arc 63 (hantavirus_outbreak) lacks sufficient non-price confirmation evidence: the predicted market probability of large-scale spread is only around 0.06, with strengthen_streak=0 and days_since_event=43.7, indicating that the signal is outdated and unverified. Additionally, the premium for this topic has already been factored into the market (price_in_excess marked as True), and option chain liquidity is sparse; therefore, there is no support for directional positions in a 1-3 month timeframe. Although macro liquidity is supportive of risk assets, it constitutes non-directional support and cannot serve as non-price evidence to establish a long position. |
| 2026-07-11 | Neutral | 0.01 | Maintain neutral. The non-price evidence provided by Arc 63 (hantavirus_outbreak) is insufficient to support a long or short position for 1-3 months: the predicted market probability of large-scale spread, yes_prob, is only around 0.06, and trading volume is limited. Strengthen_streak=0 and days_since_event=42.7 indicate that the signal is outdated and not confirmed by non-price evidence. Furthermore, the relevant premium associated with this topic has been clearly factored into the price (price_in_excess marked as True), making it unsuitable to establish a directional position based on this arc, with confidence remaining extremely low. |
| 2026-07-10 | Neutral | 0.01 | Maintain neutral. The non-price evidence provided by Arc 63 (hantavirus_outbreak) is insufficient to support a position build in 1-3 months: the predicted likelihood of large-scale spread is very low, and trading volume is small. The option IV chain is marked as sparse, which does not constitute directional basis. This arc is an old signal (days_since_event ≈ 42, strengthen_streak=0, weaken_streak=17), and the price has significantly factored in the theme premium (price_in_excess flagged=True), thus reducing the marginal value of information and confidence. |
| 2026-07-09 | Neutral | 0.03 | Maintain neutral. The rationale remains based on non-price evidence provided by arc 63 (hantavirus_outbreak): the probability of a large-scale hantavirus outbreak is predicted to be very low, the option chain is marked as chain_quality=sparse (IV lacks sufficient information), and recent central bank decisions have been consistent with expectations, providing no independent reason for a medium-term position. Additionally, it should be noted that the event has already been partially priced into market prices, and given that more than 40 days have passed since the trigger, which is longer than typical half-life, the marginal information value has diminished, thus lacking non-price evidence to change the direction of the position in the short term. |
| 2026-07-08 | Neutral | 0.03 | Maintain neutral. The driving force remains the non-price evidence provided by arc 63 (hantavirus_outbreak): the probability of a large-scale hantavirus outbreak is predicted to be very low (Manifold yes_prob ≈0.06, with limited trading volume), and the XBI option chain is marked as chain_quality=sparse (insufficient implied volatility information for position-taking). Furthermore, recent central bank decisions have been consistent with expectations, providing no macroeconomic stimulus. Additionally, there has been a significant price increase following the event trigger, which occurred about 40 days ago, well beyond the typical half-life of ~30 days, partially realizing the attention premium. Therefore, in the short term, there is no independent non-price quantitative rationale to change the position direction. |
| 2026-07-07 | Neutral | 0.03 | Maintain neutral. The driving factors remain the non-price evidence provided by arc 63 (hantavirus_outbreak): the predicted market probability of a large-scale hantavirus outbreak is extremely low (Manifold yes_prob ≈0.06, with limited volume), and the option chain is marked as chain_quality=sparse (insufficient implied volatility information to form a trading position). Additionally, recent central bank rate decisions have been consistent with expectations, providing no macroeconomic stimulus. Given these thin and low-confidence non-price signals, there are no sufficient reasons to change the position direction in the next 1-3 months; therefore, maintain neutral with very low confidence. |
| 2026-07-06 | Neutral | 0.03 | Maintain neutral. The driving forces remain the non-price evidence provided by arc 63 (hantavirus_outbreak): the market/Manifold predicts a very low probability of a large-scale hantavirus outbreak (≈0.06, with limited volume), and the option chain is marked as chain_quality=sparse (call IV not reliable), which cannot be used to confirm a standalone position. Meanwhile, there are no sudden policy shocks at the macro level (FOMC/ECB decisions align with expectations recently), and prices have already partially reflected relevant information. Therefore, there are no sufficient non-price reasons to change the stance within a 1-3 month horizon. |
| 2026-07-05 | Neutral | 0.03 | Maintain neutral. The rationale is based on non-price evidence provided by arc 63 (hantavirus_outbreak): the predicted probability of a large-scale hantavirus outbreak is very low (Manifold ≈0.06, Polymarket ≈0.01), with limited trading volume; option chain information is incomplete (call IV missing), and there are no macroeconomic triggers (FOMC/ECB stable, US NFP weaker than expected). The event remains nascent and of low weight, and the existing non-price evidence is insufficient to establish a structural reason for establishing a clear long or short position in 1-3 months. Therefore, maintain low-confidence neutrality. |
| 2026-07-04 | Neutral | 0.03 | Maintain neutral. The rationale is based on non-price evidence provided by arc 63 (hantavirus_outbreak): the probability of a large-scale hantavirus outbreak is predicted to be very low (manifold yes_prob≈0.06, with limited volume), and there are no triggering macro shocks (FOMC/ECB maintaining rates, US NFP slightly below expectations). These do not constitute structural reasons to establish a clear bullish or bearish position within 1-3 months. The IV at the options end is slightly biased towards calls but has not been attributed to specific hantavirus risk, and the information on this topic has already been partially reflected in the market. Therefore, continue with a low-confidence neutral judgment. |
| 2026-07-03 | Neutral | 0.03 | Maintain neutral. The rationale is based on non-price evidence provided by arc 63 (hantavirus_outbreak): the predicted market probability of a large-scale hantavirus outbreak is extremely low (manifold yes_prob ≈0.01/0.06), and the IV skew in the option chain (29d ATM call IV slightly above put IV) more resembles signals for general biotech catalysts or tail-risk hedging rather than specific bullish reasons for hantavirus. The arc status remains nascent, with low weight and run exceeding previous half-life assumptions, thus reducing marginal information utility, which is insufficient to support directional positions over a 1-3 month horizon. |
| 2026-07-02 | Neutral | 0.02 | Maintain neutral. The rationale is based on non-price evidence provided by arc 63 (hantavirus_outbreak): the predicted market probability of a large-scale hantavirus outbreak is very low (≈0.01–0.06), option chain samples are sparse, and put-call IV skew more likely reflects tail-hedging demand rather than clear directional bias. Additionally, the event has run for approximately 33 days, which exceeds the previously assumed half-life, leading to significant information decay. Considering these non-price signals (and that this arc state is nascent with low weight), there is insufficient evidence to support a clear long or short position in the next 1-3 months; hence, maintain neutral with low confidence. |
| 2026-07-01 | Neutral | 0.01 | Maintain neutral. The rationale is based on non-price evidence provided by arc 63 (hantavirus_outbreak): the yes_prob of a large-scale hantavirus outbreak is predicted to be very low (example value around 0.01-0.06), the sample sparsity in the XBI option chain makes the IV chain quality unreliable, and it has been running for approximately 33 days since May 29, 2026 (more than the assumed half-life of ~14 days), leading to significant information decay. These non-price indicators are not sufficient to support directional positions or opposing positions in the next 1-3 months, hence maintaining a neutral stance with very low confidence. |
| 2026-06-30 | Neutral | 0.01 | Based on the non-price evidence provided by arc 63 (hantavirus_outbreak), the predicted market probability of a large-scale hantavirus outbreak is very low (≈0.02–0.06). The option chain sample is sparse, and the IV chain quality is not credible. Historical analogy strength is relatively weak (≈0.25), and recent macro/interest rate events are in line. None of these non-price indicators are sufficient to support directional long positions in XBI over the next 1–3 months; therefore, maintaining a neutral stance with only minimal optionality/observation exposure. The current information remains consistent with the previous version, with no actionable evidence driving a change in direction. |
| 2026-06-29 | Neutral | 0.02 | Maintain a neutral stance, primarily based on the non-price evidence from arc 63 (hantavirus_outbreak) is still insufficient to support directional long positions in XBI within 1-3 months. Specifically, the yes_prob of a large-scale hantavirus outbreak is predicted to be extremely low (≈0.02), the option chain sample size is sparse, and IV chain_quality is not credible; historical analogies are weak, and macro/interest rate events are in_line. Moreover, relevant positive factors have been partially absorbed by prices. Therefore, only maintain a minimal optionality/observation exposure, which should not be used as a basis for active long positioning. |
| 2026-06-28 | Neutral | 0.02 | Maintain a neutral stance, primarily based on non-price evidence from arc 63 (hantavirus_outbreak) rather than price momentum. Specifically, the yes_prob of a large-scale hantavirus outbreak is predicted to be extremely low (≈0.01), with a sparse options chain and an untrustworthy IV chain quality. Macro/policy events are in_line, and historical analogies are also weak, none of which provide sufficient grounds to increase long exposure within the next 1-3 months. A very small position can be maintained to retain optionality on this topic but should not serve as a basis for active rebalancing or directional bets. |
| 2026-06-27 | Neutral | 0.00 | Maintain a neutral, very low confidence stance on XBI. The driving force still comes from non-price evidence provided by arc 63 (hantavirus_outbreak): the yes_prob of a large-scale hantavirus outbreak is predicted to be extremely low (≈0.01–0.02), option implied volatility samples are sparse (chain_quality = sparse), and macro data is in_line, none of which are sufficient to support establishing a meaningful long position within 1-3 months. Although there has been a clear price increase (with XBI’s outperformance against SPY significantly realized), this cannot be used as grounds for changing direction based on non-price evidence; it is recommended to retain only very small discretionary positions and maintain a watchful stance. |
| 2026-06-26 | Neutral | 0.02 | Maintain a neutral, low-confidence stance on XBI. The driving force comes from independent non-price evidence from arc 63 (hantavirus_outbreak): the predicted market probability of a large-scale hantavirus outbreak is extremely low (yes_prob ≈ 0.01–0.02), option implied volatility samples are sparse (chain_quality=sparse), and macro data (FOMC/ECB) are all in_line, none of which are sufficient to support establishing a substantive long position over the next 1-3 months. Given that these non-price signals do not constitute clear fundamental/policy or liquidity shock evidence, it is recommended to observe with minimal selective positions. |
| 2026-06-25 | Neutral | 0.03 | Maintain a neutral, low-confidence stance on XBI. The driving force comes from arc 63 (hantavirus_outbreak) providing independent non-price evidence: the predicted market/Polymarket indicates a very low probability of a large-scale hantavirus outbreak (yes_prob around 0.01–0.13), option implied volatility samples are sparse and unavailable, historical analogies show weak consistency, all of which do not support establishing a significant long position within 1-3 months; meanwhile, prices have partially reflected this, reducing the space for unrealized outperformance. Therefore, maintain an observational approach, keeping a neutral exposure with low confidence. |
| 2026-06-24 | Neutral | 0.06 | Maintain a neutral stance on XBI. The driving rationale comes from arc 63 (hantavirus_outbreak) providing independent non-price evidence: Polymarket's yes_prob for the outbreak in 2026 is only around 2%, indicating an extremely low trigger probability; additionally, the sparse sample of implied volatility in options and low historical analogy consistency do not support establishing a significant long position within 1-3 months. Given that the arc has very low weight and confidence, and prices have partially reflected this, continue to observe and maintain a neutral stance. |
| 2026-06-23 | Neutral | 0.06 | The unique arc hantavirus_outbreak (id 63) remains in an early/low-weight phase, lacking clear fundamental or policy catalysts. Independent non-price signals, such as Polymarket's approximately 2% probability for the relevant event in 2026, indicate a very low likelihood of triggering. The option IV sample is sparse, and historical analogies show low consistency, making it difficult to provide independent support. A single and low-confidence bullish narrative is insufficient to form a tradable consensus within 1-3 months, thus maintaining a neutral observation. |
| 2026-06-22 | Neutral | 0.07 | 当前唯一弧线 hantavirus_outbreak（id 63）仍属 nascent，且自上次观察进一步弱化：预测市场 Polymarket 对“2026 年出现汉坦病毒事件”的定价仅约 2%，而 Manifold 的高概率因成交极低而参考度不足。期权链样本稀疏、历史类比一致性低，亦缺乏可执行的 FDA 时间表等基本面催化。在缺少明确非价格证据支撑之下，单一且低置信度的疫情蓝图不足以驱动 1–3 个月方向性仓位，维持中性观望。 |
| 2026-06-21 | Neutral | 0.08 | The current hantavirus_outbreak (id 63) remains nascent and lacks executable non-price catalysts, thus maintaining a neutral outlook. Market forecasts suggest low probabilities of large-scale outbreaks, with no clear public health spread signals or FDA timelines yet in place. The option chain is insufficient for directional guidance due to sparse samples. A single and low-confidence epidemic scenario blueprint does not provide high confidence trading opportunities within 1-3 months, hence a watchful approach is advised. |
| 2026-06-20 | Neutral | 0.08 | The current hantavirus_outbreak (id 63) remains nascent, with only slightly elevated option IV and skew, lacking new public health spread indicators or a clear FDA timeline that could serve as executable non-price catalysts. The market's probability of a large-scale outbreak is still predicted to be low, and historical analogies are weak in consistency, making it difficult to support directional bets. Overall, with no convergence of multiple arcs and lack of substantive fundamental/policy triggers, we maintain a neutral judgment for the next 1-3 months, with low confidence. |
| 2026-06-19 | Neutral | 0.10 | The only narrative arc hantavirus_outbreak (id 63) remains nascent, low-weighted, and with its own confidence reduced to 0.03. Although there is elevated option IV and a slight positive skew, no new evidence of public health spread or clear FDA-like timelines has emerged. Market pricing for the probability of such an outbreak remains low, historical analogies are insufficient, and it does not form a non-price trigger at executable levels. Given the lack of multi-arc convergence and substantive fundamental/policy catalysts, maintain a neutral judgment over the 1-3 month horizon with low confidence. |
| 2026-06-18 | Neutral | 0.10 | The only narrative arc hantavirus_outbreak (id 63) remains nascent, low-weighted, and of low confidence with a bullish bias. There are no new triggers such as an outbreak expansion or FDA-related catalysts. Market prediction for the probability of diffusion is still relatively low (approximately 0.12–0.13). Option IV is sparse, historical analogies lack consistency, and the price has partially realized relative gains, leading to a reduction in the arc's confidence from 0.06 to 0.04. The bullish narrative is singular and weakening, lacking convergent support. Overall, maintaining a neutral judgment over a one-to-three-month horizon with low conviction. |